StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $3.00 | $2.95 | -1.67% | 0.9M |
| 05-12 | $3.45 | $3.52 | +2.03% | 9.6M |
| 05-13 | $3.45 | $3.45 | +0.00% | 1.6M |
| 05-14 | $3.61 | $4.16 | +15.24% | 3.7M |
| 05-15 | $4.13 | $4.13 | -0.12% | 0.3M |
No sell-side coverage available for MGNX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for MGNX.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $20.77M | $149.50M | $108.27M | $35.43M |
Operating Income | $-33.44M | $-72.84M | $-60.74M | $-79.38M |
Net Income | $-36.77M | $-74.62M | $-60.47M | $-36.25M |
EPS (Diluted) | $-0.58 | $-1.18 | $-0.96 | $-1.23 |
Total Assets | $217.87M | $256.85M | $270.76M | $245.42M |
Total Liabilities | $196.68M | $201.25M | $203.76M | $198.80M |
Cash & Equivalents | $66.52M | $57.22M | $80.13M | $130.69M |
Free Cash Flow OCF − CapEx | $-36.16M | $-82.95M | $-125.73M | $-95.12M |
Shares Outstanding | 63.56M | 63.32M | 63.26M | 63.21M |
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.